Why Is the Health Economics and Outcomes Research (HEOR) Market Growing So Rapidly Worldwide?

The Health Economics and Outcomes Research (HEOR) market has evolved into one of the most crucial pillars of modern healthcare decision-making. As pharmaceutical companies, healthcare providers, and government bodies increasingly prioritize value-based care, HEOR has become indispensable for demonstrating the economic and clinical value of drugs, medical devices, and healthcare interventions. With a global market value of USD 1.50 Billion in 2024, the demand for HEOR services is rising rapidly due to strict regulatory pressures, increasing healthcare spending, and the need for real-world data (RWD) insights. The market is projected to grow at a strong CAGR of 13.50%, reaching USD 5.32 Billion by 2034.

Market Overview

The HEOR industry plays a pivotal role in supporting healthcare systems worldwide as they shift from fee-for-service to value-based care. Today, decision-makers want clear evidence that a treatment is effective, safe, cost-efficient, and beneficial in real-world settings. This is where HEOR becomes essential. It integrates economic modelling, real-world data analytics, clinical outcomes research, health technology assessment (HTA), and market access strategies to guide pricing, reimbursement, and regulatory decisions.

The significance of HEOR has grown due to:

• Rising global healthcare expenditure

• Increasing unmet medical needs

• Pressure to justify high drug/therapy prices

• Emerging digital tools for generating real-world evidence

• Growing use of HEOR to strengthen reimbursement applications

Pharmaceutical and biotech companies rely heavily on HEOR to demonstrate value to regulators, insurers, and policymakers.

Key Market Drivers

1. Increasing Importance of Value-Based Healthcare

Healthcare systems across the world are shifting toward value-based models that reward outcomes rather than procedures. HEOR provides the evidence required to measure and demonstrate value, making it a key driver of market growth.

HEOR supports value-based care by:

• Demonstrating real-world effectiveness

• Supporting cost-effectiveness analyses

• Providing long-term budget impact models

• Helping identify the best therapeutic options

2. Rapid Growth in Real-World Data (RWD) and Real-World Evidence (RWE)

The availability of electronic health records (EHR), patient registries, wearable devices, and insurance claims has revolutionized the HEOR landscape.

Why RWE is important:

• Acts as evidence for regulatory submissions

• Helps understand real-world performance of therapies

• Supports product differentiation

• Enables patient-centered decision-making

Regulatory bodies like the FDA, EMA, and PMDA are increasingly encouraging the use of RWD in submissions, further accelerating the market.

3. Rising Drug Development Costs

Developing a new drug costs billions of dollars and may take more than a decade. HEOR minimizes the financial risks by providing predictive modelling to estimate product success, pricing potential, and market access feasibility.

4. Growing Mergers, Acquisitions, and Collaborations

Major life sciences and consulting companies are acquiring HEOR firms to strengthen service offerings. These strategic partnerships help expand global research infrastructure and improve analytical capabilities.

5. Increasing Demand for HEOR in Emerging Markets

Countries in Asia Pacific, Latin America, and the Middle East are strengthening healthcare systems and adopting HTA frameworks, increasing demand for HEOR-based evaluations.

Market Segmentation

By Service

1. Economic Modelling / Evaluation

Economic modelling is one of the most in-demand HEOR services. It helps estimate treatment costs, long-term health outcomes, and overall healthcare impact. Models include:

• Cost-effectiveness analysis (CEA)

• Cost-utility analysis (CUA)

• Budget impact analysis (BIA)

• Cost-benefit analysis (CBA)

These models support pricing, reimbursement, and health technology assessment decisions.

2. Real-World Data Analysis and Information Systems

RWD services involve:

• Data mining

• Predictive analytics

• AI-based modelling

• Evidence generation from wearable devices

• Claims database analysis

This segment is experiencing enormous growth due to increasing digitalization.

3. Clinical Outcomes Research

This segment measures treatment outcomes such as quality of life, adherence, safety, and long-term effectiveness. Patient-reported outcome measures (PROMs) are a major component.

4. Market Access Solutions and Reimbursement

These services help companies position their products in competitive markets and secure reimbursement approvals. They include:

• Value dossier creation

• HTA submission support

• Payer negotiation strategies

• Pricing analytics

5. Others

Includes epidemiology studies, systematic literature reviews, and evidence synthesis frameworks.

By Service Provider

1. Consultancy Firms

Consultancies dominate the HEOR market because they provide comprehensive services ranging from economic modelling to RWE generation. These firms support biotech and pharma companies from clinical development through market launch.

2. Contract Research Organizations (CROs)

CROs are increasingly adding HEOR to their portfolios due to rising demand for integrated clinical and economic research. Their global reach and advanced infrastructure give them a competitive advantage.

By End User

1. Healthcare Providers

Hospitals and clinical networks use HEOR insights to:

• Improve patient outcomes

• Optimize resource utilization

• Evaluate new medical technologies

2. Healthcare Payers

Insurance companies depend on HEOR for:

• Reimbursement decisions

• Coverage policies

• Assessing economic burden

3. Biotech / Pharma Companies

This is the largest end-user segment. Pharmaceutical manufacturers rely heavily on HEOR to:

• Support regulatory approvals

• Justify pricing

• Strengthen market access

• Differentiate products

4. Government Organizations

Government agencies use HEOR to evaluate public health interventions and optimize healthcare spending.

5. Others

Includes research institutes, non-profits, and patient advocacy groups.

Regional Insights

1. North America

The largest market due to advanced healthcare infrastructure, presence of major pharma companies, and strong HTA frameworks. The U.S. leads in RWE adoption.

2. Europe

The region has strict reimbursement and HTA guidelines, making HEOR crucial. The U.K., Germany, France, and Scandinavia are top adopters.

3. Asia Pacific

Fastest-growing market driven by rising healthcare spending, increasing clinical trials, and adoption of HTA systems in Japan, South Korea, China, and India.

4. Latin America

Moderate growth due to rising pharmaceutical investments and increasing demand for cost-effective healthcare strategies.

5. Middle East & Africa

Growth is supported by improving healthcare systems and rising research collaborations in UAE, Saudi Arabia, and South Africa.

Market Trends

Integration of AI and Machine Learning in HEOR

AI is being used to enhance predictive modelling, simulate patient outcomes, and process large-scale real-world datasets.

Increasing Adoption of Digital Health Tools

Wearables and mobile health apps provide continuous patient data, enriching RWE quality.

Demand for HEOR in Rare Diseases and Orphan Drugs

With high treatment costs, HEOR is vital for reimbursement of rare disease therapies.

Expansion of HTA Agencies

Countries worldwide are establishing HTA bodies, increasing demand for HEOR insights.

Shift Toward Patient-Centred in Clinical Outcomes

PROMs are becoming essential for measuring success beyond clinical endpoints.

Competitive Landscape

Leading companies dominating the Health Economics and Outcomes Research (HEOR) market include:

• McKesson Corporation

• Axtria

• Cardinal Health

• Avalon Health Economics

• Medlior

• IQVIA

• Pharmalex GmbH

• ZS Associates

• Deloitte

• Cytel

These organizations specialize in a range of HEOR services, including data analytics, economic modelling, strategic consulting, and global value dossier development.

Future Outlook

The future of the HEOR market is exceptionally promising. Key predictions for 2025–2034 include:

• Increasing use of AI and machine learning in real-world analytics

• Stronger integration of RWE with clinical trial data

• Rising demand for personalized and precision-based economic modelling

• Greater global adoption of HTA frameworks

• Expansion of HEOR applications into digital therapeutics and gene therapies

• More cross-industry collaborations and M&A activities

As healthcare costs continue to rise, HEOR will remain at the forefront of healthcare decision-making.

Find More Reports

Dental Equipment Market

India Vitamin Gummies Market

India Medical Gases Market

Osteoarthritis Therapeutics Market

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.

Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

Media Contact:

Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com